最新！又2款创新器械获批上市！

Core Viewpoint - The article highlights the approval of two innovative medical devices in China, indicating a growing trend in the development and registration of advanced medical technologies in the country [2][5]. Group 1: Product Overview - The "TaminoVIA® Intracranial Aneurysm Assisting Embolization Stent" developed by Jiangsu Changyida Medical Technology Co., Ltd. is designed to assist in the treatment of intracranial aneurysms using spring coils [4]. - The "TwiFlow™ Pulmonary Artery Thrombectomy System" by Morning Star (Nantong) Medical Devices Co., Ltd. is aimed at treating pulmonary embolism, a critical cardiovascular condition with high morbidity and mortality rates [13][16]. Group 2: Clinical Value - The TaminoVIA® stent offers clinical advantages such as reduced vascular wall damage, improved neck closure effectiveness, and enhanced distal operability, potentially improving patient treatment experiences and outcomes [11]. - The TwiFlow™ system provides a direct, rapid, and low-complication risk solution for pulmonary embolism, which may enhance early survival rates and long-term quality of life for patients [21]. Group 3: Company Profiles - Jiangsu Changyida Medical Technology Co., Ltd. is a high-tech innovative enterprise integrating research, production, and marketing, focusing on neurointervention and neuroregulation treatments [12]. - Morning Star (Nantong) Medical Devices Co., Ltd. specializes in the research, production, and sales of cardiopulmonary interventional devices, having developed key products such as artificial heart valves and thrombectomy devices since its establishment in April 2021 [21].